AUTHORS
Rania Abdelaziz, Priyansh Faldu2, Merry Nakhleh3, Yassin Bashir, MD4, Shraddha Patel5, Muhammad Yousuf6, Aysel Bayraktar7, Shivani Udyawar8, Kaaren Reichard, MD9, Rong He, MD10, Cinthya J. Zepeda Mendoza11, Animesh Pardanani, PhD, MBBS12, Naseema Gangat, MBBS13, Ayalew Tefferi, MD14
AFFILIATIONS
1 Mayo Clinic, Rochester, MN, United States, Mayo Clinic, Rochester, MN, United States
2 Mayo Clinic, Rochester, MN, United States
3 Mayo Clinic, Rochester, MN, United States
4 Mayo Clinic, Rochester, MN, United States
5 Mayo Clinic, Rochester, MN, United States
6 Mayo Clinic, Rochester, MN, United States
7 Mayo Clinic, Rochester, MN, United States
8 Mayo Clinic, Rochester, MN, United States
9 Mayo Clinic, Rochester, MN, United States
10 Mayo Clinic, Rochester, MN, United States
11 Mayo Clinic, Rochester, MN, United States
12 Mayo Clinic, Rochester, MN, United States
13 Mayo Clinic, Rochester, MN, United States
14 Mayo Clinic, Rochester, MN, United States
ABSTRACT
Background
Primary myelofibrosis (PMF) is characterized by shortened survival as well as poor quality of life. The latter stems from anemia, splenomegaly, and constitutional symptoms/cachexia. JAK2 inhibitor therapy is often effective, although incompletely and transiently, in controlling splenomegaly and symptoms in PMF but not anemia, which remains an unmet need. The current study examines the scope of the anemia problem in PMF with emphasis on trajectory and performance of current drug therapies in achieving response, strictly defined by the revised International Working Group-European LeukemiaNet criteria [IWG-MRT-ELN] (Blood 2024;144:1813).
Methods
Patients were recruited from existing Mayo Clinic databases and the study conducted under institutional review board approved protocols. Diagnoses were according to the International Consensus Classification criteria (Blood 2022;140:1200) and severity of anemia and response adjudication were established following IWG-MRT-ELN criteria (Blood 2024;144:1813).
Results
A total of 1,004 molecularly-annotated patients with PMF (median age 65 years; 64% males) were considered. At baseline, 805 (80%) patients manifested anemia of varying severity: 324 (32%) mild (Hgb 11-13.4 g/dl in males or 10-11.9 g/dl in females), 200 (20%) moderate (Hgb 9-10.9 g/dl in males or 8-9.9 g/dl in females), and 280 (28%) severe (transfusion-dependent anemia [TDA] or Hgb <9 g/dl in males or <8g/dl in females). In multivariable analysis, the presence of anemia (or severe anemia) was associated with older age, thrombocytopenia, lower leucocyte count, constitutional symptoms, and mutations involving CALR (type 1), MPL, and U2AF1-Q157 (p<0.05 in all instances); on the other hand, JAK2-mutated patients were less likely to be anemic (p<0.01).
Progressive anemia (i.e., new onset or change in severity) was documented in 25%, 34%, and 41% of patients over the first 1, 3, and 5 years, respectively. Among the 199 patients without anemia at baseline, 66% of evaluable cases developed anemia in the first 5 years, including 10% with new-onset TDA (66%/10%). The corresponding figures for worsening anemia in patients with mild or moderate anemia at baseline were 44%/16% and 32%/18%, respectively.
Anemia-directed drug therapies employed during the first 5 years were documented in 547 patients and specific therapy included erythropoiesis-stimulating agents (23%), thalidomide (12%), danazol (7%), momelotinib (7%), pomalidomide (6%), and androgens (4%). Anemia response was documented in 146 (27%) patients and included major (N=93; 17%) and minor (N=53; 10%) responses.
Median survival for patients with no, mild, moderate, or severe anemia, at baseline, was 13, 10, 5, and 3 years, respectively (p<0.03 across all categories). As expected, baseline severity of anemia was directly correlated with inferior survival, in both univariate and multivariable analyses that included other clinical and genetic risk factors (p<0.05 across all anemia subcategories). Additional adverse impact on survival, for new or worsening anemia, was apparent in univariate (p<0.01) but not multivariable (p=0.07) analysis that accounted for other risk factors. Among patients receiving treatment for anemia (N=547), the achievement of response was associated with improved survival (p<0.01; HR 0.7, 95% CI 0.55-0.90)) with no difference between major and minor anemia response; significance was sustained during multivariable analysis that included other clinical and genetic risk factors (p<0.01) but limited to patients with severe/moderate (p<0.01) vs. mild/no (p=0.56) anemia.
TDA was documented in 23% of patients at baseline and new-onset TDA was observed at 8%, 15%, 15% of evaluable patients at 1, 3, and 5 years, respectively. In multivariable analysis, risk factors for developing new-onset TDA included leukocyte count >25 x 109/L (p<0.01), baseline severe anemia (p<0.01), and unfavorable karyotype (p<0.01).
Conclusion
The current study documents the burden of anemia in PMF, clinical and molecular correlates, trajectory in the first 5 years of diagnosis, and impact on survival. The study also highlights the inadequacy of current anemia-directed therapeutics, providing a framework of reference to gauge the performance of new drugs. Interestingly, achievement of major or minor anemia response, following conventional therapy, was independently associated with improved survival.
DISCLOSURES
Rania Abdelaziz: No relevant conflicts of interest to declare.